PMC5772496_01
Chest X-ray showing the primary lung adenocarcinoma lesion: (A) before crizotinib treatment and (B) after crizotinib treatment.
10.1177_1179547617749615-fig1.jpg
PMC5772496_01_10.1177_1179547617749615-fig1.jpg
fig1-1179547617749615
Chest X-ray was ordered revealing an ill-defined enhancing right hilar mass suggestive of malignancy (Figure 1A). After 2 months of crizotinib treatment, chest CT scan images demonstrated a decrease in tumor size (Figure 1B) and decreased FDG uptake (Figure 2B).
Computed tomographic and positron emission tomographic images showing FDG uptake: (A) before crizotinib treatment and (B) after crizotinib treatment.
10.1177_1179547617749615-fig2.jpg
PMC5772496_01_10.1177_1179547617749615-fig2.jpg
fig2-1179547617749615
The PET-CT scan suggested abnormal increased FDG uptake in right lung (Figure 2A) and stage IIIB (T4N2M0) disease. After 2 months of crizotinib treatment, chest CT scan images demonstrated a decrease in tumor size (Figure 1B) and decreased FDG uptake (Figure 2B).